Rise Advisors’s Niagen Bioscience NAGE Stock Holding History

Rise Advisors’s Portfolio NAGE Stock Details NAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-53	Closed	-$494	–	1519
2025 Q3	$494	Buy	+53	New	+$535	﹤0.01%	1419

Other funds holding NAGE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tieton Capital Management Yakima, Washington $299M AUM 54.55% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Rise Advisors's NAGE Position: Q4 2025 in Review

Rise Advisors sold out of Niagen Bioscience (NAGE) in Q4 2025, closing a stake of 53 shares — an estimated $494 sold.

Rise Advisors first reported a position in NAGE in Q3 2025 and held it in 1 quarter. The position peaked at $494 in Q3 2025. 169 funds tracked by Wall St. Rank hold NAGE as of Q4 2025.

Rise Advisors reported no remaining Niagen Bioscience position as of Q4 2025 after selling out during the quarter.
Rise Advisors sold 53 Niagen Bioscience shares in Q4 2025, an estimated $494.
Rise Advisors first reported a position in Niagen Bioscience in Q3 2025 and held it in 1 quarter.
Rise Advisors's Niagen Bioscience position peaked at $494 in Q3 2025.
169 funds tracked by Wall St. Rank held Niagen Bioscience as of Q4 2025.

Based on Rise Advisors's 13F filing for Q4 2025, filed 11 Feb 2026.